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Ankle Brachial Index and Subsequent Cardiovascular Disease Risk in
Patients With Chronic Kidney Disease
Jing Chen, MD, MSc;* Emile R. Mohler, III, MD;* Pranav S. Garimella, MD; L. Lee Hamm, MD; Dawei Xie, PhD; Stephen Kimmel, MD;
Raymond R. Townsend, MD; Matthew Budoff, MD; Qiang Pan, MA; Lisa Nessel, MSS, MLSP; Susan Steigerwalt, MD;
Jackson T. Wright, MD, PhD; Jiang He, MD, PhD; for the CRIC Investigators†
Background-—The clinical implications of ankle-brachial index (ABI) cutpoints are not well defined in patients with chronic kidney
disease (CKD) despite increased prevalence of high ABI attributed to arterial stiffness. We examined the relationship of ABI with
cardiovascular disease (CVD) and all-cause mortality among CKD patients.
Methods and Results-—Three thousand six hundred twenty-seven participants without clinical peripheral artery disease (PAD) at
baseline from the Chronic Renal Insufficiency Cohort Study were included. ABI was obtained per standard protocol and CVD events
were confirmed by medical record adjudication. A U-shaped association of ABI with PAD, myocardial infarction (MI), composite
CVD, and all-cause mortality was observed. Individuals with an ABI between 1.0 and <1.4 had the lowest risk of outcomes.
Compared to participants with an ABI between 1.0 and <1.4, multiple-adjusted hazard ratios (95% confidence intervals) for those
with an ABI of <0.9, 0.9 to <1.0, and ≥1.4 were 5.78 (3.57, 9.35), 2.76 (1.56, 4.88), and 4.85 (2.05, 11.50) for PAD; 1.67 (1.23,
2.29), 1.85 (1.33, 2.57), and 2.08 (1.10, 3.93) for MI; 1.51 (1.27, 1.79), 1.39 (1.15, 1.68), and 1.23 (0.82, 1.84) for composite
CVD; and 1.55 (1.28, 1.89), 1.36 (1.10, 1.69), and 1.00 (0.62, 1.62) for all-cause mortality, respectively.
Conclusions-—This study indicates that ABI <1.0 was related to risk of PAD, MI, composite CVD, and all-cause mortality whereas
ABI ≥1.4 was related to clinical PAD. These findings suggest that ABI cutpoints of <1.0 or ≥1.4 for diagnosing PAD and ABI <1.0 for
CVD risk stratification should be further evaluated among CKD patients. ( J Am Heart Assoc. 2016;5:e003339 doi: 10.1161/
JAHA.116.003339)
Key Words: ankle brachial index • cardiovascular disease • chronic kidney disease • heart failure • mortality • myocardial
infarction • peripheral arterial disease
P atients with chronic kidney disease (CKD) have ahigher prevalence of peripheral artery disease (PAD)
compared to the general population.1–3 Data from the
National Health and Nutrition Examination Survey indicate
that 24% of persons with creatinine clearance <60 mL/min
per 1.73 m2 have prevalent PAD, defined as ankle brachial
index (ABI) <0.9, compared with only 3.7% of persons with
creatinine clearance ≥60 mL/min per 1.73 m2.1 In the
Cardiovascular Health Study, Ix et al. reported that CKD
was associated with a 2-fold increased risk for low ABI
(<0.9) and 60% increased risk for high ABI (>1.4) in older
people and that the association of CKD with a high ABI was
not explained by traditional cardiovascular disease (CVD)
risk factors.4
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Both low and high ABI have been associated with increased
CVD morbidity and mortality in the general population.5–7 In
addition, Adragao et al. reported that both low (<0.9) and high
(>1.3) ABI were independently associated with all-cause and
CVD mortality in 219 hemodialysis patients.8 Large meta-
analysis data suggested that ABI of 0.9 to 1.0 was associated
with increased risk of major coronary events, CVD, and total
mortality in the general population.6 However, there are no
published prospective studies evaluating the association of
the spectrum of ABI with PAD and other CVD outcomes, as
well as all-cause mortality in persons with CKD preceding
kidney failure.
We examined the association of baseline ABI with subse-
quent risk of PAD, myocardial infarction (MI), heart failure
(HF), CVD, and all-cause mortality among participants from
the Chronic Renal Insufficiency Cohort (CRIC) Study, a large
prospective cohort study designed to investigate risk factors
for progression of CKD and development of CVD in patients
with CKD.9
Methods
Study Participants
The design and baseline characteristics of the CRIC Study
participants have been previously described.9,10 Briefly, the
CRIC Study enrolled a racially and ethnically diverse group of
men and women ages 21 to 74 years with CKD as determined
by an age-based estimated glomerular filtration rate (eGFR) of
20 to 70 mL/min per 1.73 m2.9 A total of 3939 participants
were recruited between May 2003 and August 2008 from 7
clinical centers in the United States. Patients with cirrhosis,
human immunodeficiency virus infection, polycystic kidney
disease, or renal cell carcinoma, those on dialysis or
recipients of a kidney transplant, and those taking immuno-
suppressant drugs were excluded. We excluded 312 partic-
ipants who reported a history of lower-extremity
revascularization or amputation at baseline. The CRIC Study
protocol was approved by the institutional review boards at
each of the participating sites. Written informed consent was
obtained from all participants.
Data Collection
At the baseline examination, medical history, demographic
information, and lifestyle factors were collected by trained
research staff using standard questionnaires. Self-reported
history of clinical PAD, including claudication, amputation, or
angioplasty and procedures to open up blood vessels in the
arms or legs, was acquired. Current smokers were defined as
participants who currently smoked and had smoked >100
cigarettes in their lifetimes. Alcohol drinkers were defined as
participants who consumed >1 beverage containing alcohol
each week over the previous year. Physical activity was
estimated by total metabolic equivalent of task (MET)/week.
ABI measurements were obtained per standard protocol.11
After the participant rested supine for 5 minutes, systolic
blood pressure (BP) was measured in both arms with the
appropriate-sized arm cuff. For each leg, systolic BP in each
posterior tibial and dorsalis pedis artery was measured. All
pressures were detected with a continuous-wave Doppler
ultrasound probe. Leg-specific ABI was calculated by dividing
the higher systolic BP in the posterior tibial or dorsalis pedis
by the higher of the right or left brachial systolic BPs.
Body weight and height were each measured twice at
baseline, and the mean was used to calculate body mass
index (BMI) as weight in kilograms divided by height in meters
squared. Waist circumference was measured at the upper-
most lateral border of the iliac crest with a Gulick II tape and
repeated until 2 measures agreed within 1 cm. Three seated
BP measurements were obtained by trained and certified staff
members after >5 minutes of quiet rest and were averaged
for analysis. These measurements were performed according
to a standard protocol using an aneroid sphygmomanome-
ter.12 Hypertension was defined as systolic BP ≥140 mm Hg
and/or diastolic BP ≥90 mm Hg and/or current use of
antihypertensive medication.
Blood glucose, cholesterol, and triglycerides were mea-
sured using standard laboratory methods. Diabetes was
defined as a fasting glucose ≥126 mg/dL, or a random
glucose ≥200 mg/dL, and/or use of insulin or other antidi-
abetic medication. Serum high-sensitivity C-reactive protein
(hsCRP) and cystatin C were measured using a particle-
enhanced immunonephelometric method. Urinary albumin
was measured by radioimmunoassay. The eGFR was calcu-
lated using the re-expressed Modification of Diet in Renal
Disease equation after calibrating serum creatinine measure-
ments to isotope dilution mass-spectrometry–traceable val-
ues.13 All laboratory analyses were conducted at the CRIC
Study Central Laboratory at the University of Pennsylvania
(Philadelphia, PA) with stringent quality control.
Follow-up and Outcomes
Study participants were followed up with annual clinical visits
and 6-month telephone interviews. Clinical information on
incident CVD was extracted from hospital records by a trained
research nurse. Clinical diagnoses of CVD were adjudicated
by at least 2 physician reviewers from the outcome assess-
ment committee using standard criteria. Incident clinical PAD
was defined as a history of amputation attributed to PAD,
peripheral surgical or percutaneous revascularization proce-
dures, any arterial angioplasty, or any artery-artery bypass
graft. Deaths were confirmed by death certificate and the
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National Death Master File. We defined a composite CVD
outcome of incident MI, stroke, and total mortality. Median
duration of follow-up was 7.5 years for this analysis, and 197
participants were lost to follow-up.
Statistical Analysis
Baseline characteristics among the study participants in the
different categories of ABI were described using mean (SD) for
continuous variables and count (%) for categorical variables.
Differences were compared with the use of ANOVA for
continuous variables and the chi-square test for categorical
variables. We used restricted-cubic-spline plots to explore the
shape of the association between ABI measurements and
each clinical outcome. On the basis of our restricted-cubic-
spline plots for PAD, CVD, and all-cause mortality and the
results of previous studies,6,7,14 we selected a level of ABI of
1.0 to 1.4 as the reference category. Furthermore, ABI values
were categorized into 4 groups (<0.9, 0.9 to <1.0, 1.0 to <1.4,
and ≥1.4) in our analysis.
Cumulative event rates of incident PAD, MI, HF, and CVD,
and all-cause mortality were calculated according to ABI
groups using the Kaplan–Meier method and compared using
the log-rank test.15 We also reported the number of events
and calculated the incidence rate for each ABI group using
Poisson regression. Hazards ratios for the associations of ABI
with PAD, MI, HF, CVD, and all-cause mortality were
estimated using Cox proportional hazards models.16 Age,
race, sex, clinic site, history of CVD, diabetes, hypertension,
cigarette smoking, alcohol consumption, high school educa-
tion, physical activity (total METs/week), systolic BP, BMI,
low-density lipoprotein (LDL)-cholesterol, high-density
lipoprotein (HDL)-cholesterol, glucose, hsCRP, 24-hour albu-
minuria, eGFR, and use of medications (angiotensin convert-
ing enzyme inhibitors, angiotensin receptor blockers, beta
blockers, aspirin, and statins) were adjusted in multivariable
models. Hazard ratios and 95% confidence intervals of the
clinical CVD events and mortality were calculated for each
category of ABI using ABI of 1.0 to 1.4 as the reference
group. The assumption of proportional hazards was tested
using interaction terms with ABI groups by time for each
outcome variable and covariate. No substantial deviations
from proportionality were observed (P>0.08). All analyses
were conducted using SAS software (version 9.1; SAS
Institute Inc., Cary, NC). All P values were 2-sided, and
statistical significance was defined as P<0.05.
Results
Baseline characteristics according to ABI categories are shown
in Table 1. Participants with an ABI <0.9 were significantly
older, more likely to be female, African American, and current
smokers, but less likely to be high school graduates, physically
active, and alcohol drinkers than those with ABI of 1.0 to <1.4.
In addition, they had significantly higher BMI, waist circumfer-
ence, systolic BP, plasma glucose, hsCRP, cystatin C, and
albuminuria and lower HDL- and LDL-cholesterol and eGFR.
Proportions of participants who reported a history of clinical
CVD, hypertension, and diabetes and use of antihypertensive
medications, aspirin, and statins were significantly higher
among patients with ABI <0.9. Compared to those with ABI of
1.0 to <1.4, patients with an ABI >1.4 were older and less likely
to be female, physically active, and alcohol drinkers. Persons
with an ABI >1.4 also had significantly higher BMI, waist
circumference, systolic BP, hsCRP, cystatin C, and albuminuria,
lower HDL- and LDL-cholesterol and eGFR, and weremore likely
to have a history of clinical CVD, hypertension, and diabetes and
use antihypertensive medications and aspirin. Baseline char-
acteristics were comparable between those lost to follow-up
and those not, except systolic BP (132.126.3 vs
127.721.8 mm Hg; P=0.01) and albuminuria (0.91.7 vs
0.61.5 g/24 hours; P=0.04).
Multivariate spline regressions indicated a U-shaped
association of ABI with PAD, MI, CVD, and all-cause mortality
(Figure 1). Individuals with an ABI between 1.0 and <1.4 had
the lowest risk of developing clinical outcomes.
Kaplan–Meier plots showed that individuals with an ABI
between 1.0 and <1.4 had the lowest cumulative incidences
whereas those with an ABI <0.9 has the highest cumulative
incidences of PAD, MI, HF, CVD, and all-cause mortality
(Figure 2). Persons with an ABI ≥1.4 or ABI of 0.9 to <1.0 also
had an increased cumulative incidences of CVD events and
all-cause mortality compared to those with ABI of 1.0 to <1.4.
Table 2 shows numbers of events and event rates as well
as multiple-adjusted hazard ratios of cardiovascular diseases
and deaths associated with ABI categories. Compared to the
reference group (ABI 1.0 to <1.4) persons with an ABI <0.9
had a 5.8-fold increased risk of PAD whereas those with ABI
of 0.9 to <1.0 had a 2.8-fold increased risk of PAD after
adjustment for multiple important CVD risk factors. Likewise,
individuals with an ABI ≥1.4 had a 4.9-fold increased risk of
PAD. The relationship of other traditional risk factors with the
CVD outcomes and mortality are presented in Table S1; all
significant traditional risk factors were adjusted in the final
Cox proportional hazards models (Table 2).
Compared to the reference group, individuals with an ABI
<0.9 and ABI of 0.9 to <1.0 had a 1.7- and 1.9-fold increased
risk of MI, respectively, after multiple adjustment. Individuals
with an ABI <0.9 also had a 27% increased risk of HF.
Furthermore, individuals with an ABI <0.9 and ABI of 0.9 to
<1.0 had a 51% and 39% increased risk of composite CVD,
respectively. However, an ABI >1.4 was not significantly
associated with risk of CVD or all-cause mortality (Table 2).
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Compared to ABI 1.0 to <1.4, ABI <0.9 and ABI 0.9 to <1.0
were significantly associated with a 56% and 34% increase in
all-cause mortality after adjustment for multiple risk factors
whereas ABI >1.4 was not significantly associated with all-
cause mortality after multiple adjustment.
Discussion
Our study indicated that an ABI of <1.0 was strongly and
significantly associated with an increased risk of clinical PAD,
MI, composite CVD, and all-cause mortality among patients
with CKD. In addition, an ABI ≥1.4 was strongly and
significantly associated with risk of developing clinical PAD.
These associations were independent of albuminuria and
eGFR in addition to other established CVD risk factors and
current treatment.
These findings have important clinical and public health
implications, because patients with CKD are at an increased
risk of developing PAD.1,2 In addition, CKD patients with PAD
have a very high risk of CVD and all-cause mortality.8,17
Proper detection and intervention are the key to prevent
adverse CVD outcomes associated with PAD among patients
with CKD. ABI is a simple, inexpensive, and noninvasive
measure of subclinical PAD.3 Traditionally, an ABI cutpoint of
Table 1. Baseline Characteristics of Study Participants According to ABI
Characteristic
Ankle Brachial Index
P Value for
Differences
<0.9
(n=542)
0.9 to <1.0
(n=571)
1.0 to <1.4
(n=2430)
≥1.4
(n=84)
Age, y 62.6 (9.1) 58.2 (10.9) 57.0 (11.3) 58.4 (10.1) <0.001
Female, n (%) 276 (50.9) 331 (58.0) 1033 (42.5) 28 (33.3) <0.001
Race/ethnicity, n (%)
White 177 (32.7) 202 (35.4) 1110 (45.7) 35 (41.7)
African American 291 (53.7) 283 (49.6) 926 (38.1) 27 (32.1) <0.001
Other 74 (13.7) 86 (15.1) 394 (16.2) 22 (26.2)
High school graduates, n (%) 382 (70.5) 447 (78.3) 2007 (82.6) 65 (77.4) <0.001
Physical activity, MET/week 172.0 (126.1) 199.3 (161.5) 210.1 (147.9) 176.8 (140.2) <0.001
Current smoking, n (%) 109 (20.1) 96 (16.8) 258 (10.6) 8 (9.5) <0.001
Alcohol drinking, n (%) 278 (51.3) 354 (62.0) 1629 (67.0) 50 (59.5) <0.001
Body mass index, kg/m2 32.7 (8.3) 32.8 (8.0) 31.5 (7.5) 33.9 (7.5) <0.001
Waist circumference, cm 108.0 (18.0) 106.7 (18.2) 104.6 (17.1) 111.2 (15.7) <0.001
Systolic blood pressure, mm Hg 133.9 (23.8) 127.6 (22.2) 126.6 (21.5) 131.8 (22.7) <0.001
Plasma glucose, mg/dL 119.3 (49.4) 115.8 (53.5) 111.8 (48.6) 112.9 (47.0) <0.001
HDL-cholesterol, mg/dL 45.5 (13.4) 48.1 (15.3) 48.2 (15.9) 45.0 (15.7) 0.001
LDL-cholesterol, mg/dL 100.9 (33.8) 104.4 (36.0) 103.7 (35.1) 91.6 (37.4) 0.005
hsCRP, mg/L 7.43 (13.34) 6.74 (13.44) 4.85 (7.76) 5.47 (7.09) <0.001
eGFR, mL/min per 1.73 m2 38.4 (12.0) 42.3 (13.6) 44.6 (13.6) 40.4 (13.4) <0.001
Cystatin C, mg/L 1.72 (0.55) 1.53 (0.57) 1.43 (0.51) 1.73 (0.58) <0.001
Albuminuria, g/24 hours 0.76 (1.79) 0.51 (1.39) 0.62 (1.46) 1.08 (2.22) 0.004
History of clinical CVD, n (%) 289 (53.3) 173 (30.3) 603 (24.8) 32 (38.1) <0.001
Hypertension, n (%) 508 (93.7) 500 (87.6) 2024 (83.3) 73 (86.9) <0.001
Diabetes, n (%) 341 (62.9) 273 (47.8) 998 (41.1) 59 (70.2) <0.001
Use of RAAS blockers, n (%) 409 (75.9) 378 (66.8) 1617 (67.0) 60 (71.4) 0.001
Use of b-blockers, n (%) 328 (60.9) 275 (48.6) 1085 (44.9) 49 (58.3) <0.001
Use of aspirin, n (%) 300 (55.7) 236 (41.7) 917 (38.0) 41 (48.8) <0.001
Use of statins, n (%) 373 (69.2) 295 (52.1) 1221 (50.6) 44 (52.4) <0.001
All values reported as mean (SD) or n (%). SI conversion factors: to convert glucose from mg/dL to mmol/L, multiply by 0.0555; LDL and HDL from mg/dL to mmol/L, multiply by 0.0259;
and hsCRP from mg/dL to nmol/L, multiply by 9.524. ABI indicates ankle brachial index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density
lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MET, metabolic equivalent of task; RAAS, renin-angiotensin-aldosterone system.
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<0.9 was considered subclinical peripheral arterial atheroscle-
rosis. However, we observed a 2.8- or 4.9-fold increase in risk
of clinical PAD among participants with ABI of 0.9 to <1.0 or
ABI ≥1.4, respectively. These results suggest that ABI
cutpoints for the clinical diagnosis of PAD, as well as CVD
risk stratification among patients with CKD, may need to be
further evaluated.
Our study is the first to report that an ABI ≥1.4 is
significantly related to future clinical PAD among predialysis
CKD patients after adjusting for established CVD risk factors.
In a previous cross-sectional study, ABI >1.4 was shown to
be associated with leg ulcers in the general population.5 ABI
≥1.4 was associated with vascular calcification in peripheral
and distal arteries among dialysis patients.8 Vascular
calcification is highly prevalent in CKD patients.18,19 Medial
arterial calcification is common in CKD patients and causes
arterial stiffness, a decrease in perfusion, and impairment of
collateral circulation formation,20–23 which may contribute to
PAD. Our study suggests that ABI ≥1.4 is not significantly
associated with MI, HF, composite CVD, and all-cause
mortality in patients with CKD. A previous meta-analysis
suggested that ABI >1.4 was associated with total mortality,
but not major coronary events, in the general population.6
Adragao et al. reported that ABI >1.3 was associated with
increased all-cause and CVD mortality among 219 dialysis
patients.8 The inconsistent findings may be partially
attributed to the small sample size in the ABI ≥1.4 group
in our study. Future studies are warranted to confirm the
Cardiovascular Disease All-cause Mortality 
Peripheral Artery Disease Myocardial Infarction Heart Failure 
Figure 1. Spline plots of multiple-adjusted hazard ratios and 95% confidence intervals of peripheral artery disease, myocardial
infarction, heart failure, composite cardiovascular disease, and all-cause mortality associated with baseline ankle-brachial index. In each
plot, the solid blue line represents the point estimate and the dotted black lines represent 95% confidence intervals. ABI indicates ankle-
brachial index.
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association of ABI ≥1.4 with PAD, MI, CVD, and mortality in a
large cohort of CKD patients.
Our study found that ABI of 0.9 to <1.0 was significantly
related with future clinical PAD, MI, composite CVD, as well as
all-cause mortality among predialysis CKD patients after
adjusting for established CVD risk factors. Previous studies in
non-CKD patients suggested that ABI of 0.9 to <1.0 predicted
CVD and total mortality.6,24 The American Heart Association
(AHA) suggested that ABI should be interpreted according to
the a priori probability of PAD, and values between 0.91 and
1.00 should be considered borderline.25 However, the sensi-
tivity and specificity of ABI 0.91 to 1.00 as a cutpoint to detect
PAD compared to an angiographic finding of ≥50% stenosis in
patients with PAD were varied, and its predictive value for
future PAD events remains unknown.25 Our study reported that
ABI of 0.9 to <1.0 was associated with a 2.8-fold higher risk of
future PAD, suggesting that ABI of 0.9 to <1.0 might have
clinical significance for the CKD population without history of
clinical PAD. Further studies are needed to confirm the
association between ABI of 0.9 to <1.0 and incident clinical
PAD and to evaluate ABI of <1.0 as a cutpoint for diagnosis of
PAD among CKD patients. In addition, ABI of 0.9 to <1.0 was
considered borderline in terms of cardiovascular risk in the
general population per the AHA Scientific Statement,25
whereas our findings provide additional evidence that an ABI
of 0.9 to <1.0 represents significantly high risk for further MI,
CVD, and all-cause mortality among CKD patients, who may
benefit from earlier intervention or intensive treatment.
Figure 2. Kaplan–Meier estimates of cumulative incidence of peripheral artery disease, myocardial
infarction, heart failure, composite cardiovascular disease, and all-cause mortality. ABI indicates ankle-
brachial index.
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There are several strengths of our study. This is the first
large prospective cohort study to examine ABI cutpoints with
risk of PAD, other CVD, and mortality among patients with
CKD. Numerous important confounding factors were collected
and adjusted in the multivariable models. Therefore, our study
should provide a valid and reliable assessment of ABI
cutpoints with the outcomes. Several limitations of our study
should be noted. First, the number of patients with an ABI
>1.4 was small in our study. Future larger prospective cohort
studies are needed to more precisely estimate the risk
associated with ABI >1.4 among patients with CKD. Second, a
single measurement of ABI at baseline was used instead of
the mean of multiple measurements. However, ABIs were
measured by trained and certified study staff. Third, we did
not include patients with symptoms, such as rest pain or
vascular ulceration, alone as clinical PAD because those
Table 2. Multivariable Adjusted Hazard Ratios of Cardiovascular Diseases and Mortality Associated With ABI
Outcome
No. of
Events
Incidence,
per 1000
Age, Sex, Race, and Clinic Site-Adjusted Multivariable-Adjusted*
Hazard Ratio
(95% CI) P Value
Hazard Ratio
(95% CI) P Value
PAD
<0.9 53 1.67 8.04 (5.17, 12.50) <0.001 5.78 (3.57, 9.35) <0.001
0.9 to <1.0 21 0.56 2.98 (1.72, 5.15) <0.001 2.76 (1.56, 4.88) <0.001
1.0 to <1.4 37 0.22 Ref Ref
≥1.4 7 1.41 5.03 (2.21, 11.46) <0.001 4.85 (2.05, 11.5) <0.001
P value for nonlinear trend <0.001 <0.001
MI
<0.9 79 2.55 2.70 (2.02, 3.61) <0.001 1.67 (1.23, 2.29) 0.001
0.9 to <1.0 57 1.58 2.03 (1.47, 2.79) <0.001 1.85 (1.33, 2.57) <0.001
1.0 to <1.4 129 0.79 Ref Ref
≥1.4 11 2.33 2.59 (1.39, 4.82) 0.003 2.08 (1.10, 3.93) 0.024
P value for nonlinear trend <0.001 <0.001
HF
<0.9 142 4.89 2.10 (1.70, 2.59) <0.001 1.27 (1.01, 1.58) 0.039
0.9 to <1.0 86 2.43 1.22 (0.96, 1.56) 0.14 1.10 (0.85, 1.42) 0.48
1.0 to <1.4 289 1.84 Ref Ref
≥1.4 15 3.12 1.37 (0.81, 2.31) 0.24 0.89 (0.52, 1.51) 0.66
P value for nonlinear trend <0.001 0.19
CVD (MI, stroke, and total mortality)
<0.9 247 7.89 2.25 (1.88, 2.69) <0.001 1.39 (1.15, 1.68) <0.001
0.9 to <1.0 169 4.53 1.51 (1.23, 1.85) <0.001 1.39 (1.15, 1.68) <0.001
1.0 to <1.4 479 2.84 Ref Ref
≥1.4 27 .27 1.26 (0.79, 2.01) 0.32 1.23 (0.82, 1.84) 0.32
P value for nonlinear trend <0.001 <0.001
All-cause mortality
<0.9 200 5.85 2.21 (1.89, 2.60) <0.001 1.55 (1.28, 1.89) <0.001
0.9 to <1.0 129 3.23 1.54 (1.29, 1.85) <0.001 1.36 (1.08, 1.69) 0.005
1.0 to <1.4 364 2.09 Ref Ref
≥1.4 19 3.33 1.54 (1.04, 2.27) 0.031 1.00 (0.62, 1.62) 1.00
P value for nonlinear trend <0.001 <0.001
*Adjusted for age, race, sex, clinic site, history of cardiovascular disease, diabetes, hypertension, current smoking, alcohol use, high school education, physical activity, systolic blood
pressure, body mass index, LDL- and HDL-cholesterol, plasma glucose, high-sensitivity C-reactive protein, 24-hour excretion of albuminuria, estimated glomerular filtration rate, and use of
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aspirin, or statins. ABI indicates ankle brachial index; CVD, cardiovascular disease; HF, heart
failure; MI, myocardial infarction; PAD, peripheral artery disease.
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symptoms are nonspecific and are not clearly described in
detail in the study questionnaire. This could potentially result
in lower outcome rates and reduced statistical power, but
decreases the chance of misclassification. In addition, a
recent study has suggested that an alternative ABI method
utilizing the ratio of the lower of dorsalis pedis and posterior
tibial pressures to the higher of the right or left brachial
systolic pressures may provide better prediction of CVD
mortality compared to the traditional method.26 However, the
alternative method is not validated for clinical use, particularly
in the CKD population. Finally, time-dependent covariates,
such as medication use during follow-up, were not adjusted in
this analysis. In future research, more-sophisticated statistical
methods, such as marginal structural models, could be used
to study potential causal relationships between change in ABI
and the clinical outcomes adjusting for time-dependent
covariates (ie, medication use).27,28
In conclusion, our study indicates that ABI <1.0 and ≥1.4 are
significantly associated with future clinical PAD among CKD
patients. In addition, ABI <1.0 is significantly associated with
increased risk of MI, CVD, and all-cause mortality among CKD
patients. These findings indicate that the ABI cutpoints for the
diagnosis of PAD may need to be further evaluated in patients
with CKD, and confirmatory tests to diagnose PAD may be
beneficial among CKD patients with ABI of 0.9 to <1.0.
Furthermore, ABI <1.0 may be useful for risk stratification of
CVD and all-cause mortality among patients with CKD.
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SUPPLEMENTAL MATERIAL 
 Table S1: The Hazard Ratios of Clinical Outcomes Associated with Traditional Risk Factors 
Variables 
PAD MI CHF CVD Death 
Hazard Ratio 
(95% CI) 
Overall P 
value 
Hazard Ratio 
(95% CI) 
Overall P 
value 
Hazard Ratio 
(95% CI) 
Overall P 
value 
Hazard Ratio 
(95% CI) 
Overall P 
value 
Hazard Ratio 
(95% CI) 
Overall P 
value 
ABI 
ABI <0.9 
5.78  
(3.57, 9.35) 
<0.0001 
1.67  
(1.23, 2.29) 
0.0002 
1.27  
(1.01, 1.58) 
0.19 
1.51  
(1.27, 1.79) 
<0.0001 
1.55  
(1.28, 1.89) 
<0.0001 
ABI 0.9-<1.0 
2.76  
(1.56, 4.88) 
  
1.85  
(1.33, 2.57) 
  
1.10  
(0.85, 1.42) 
  
1.39  
(1.15, 1.68) 
  
1.36  
(1.1, 1.69) 
  
ABI ≥1.4 
4.85  
(2.05, 11.5) 
  
2.08  
(1.10, 3.93) 
  
0.89  
(0.52, 1.51) 
  
1.23  
(0.82, 1.84) 
  
1.00  
(0.62, 1.62) 
  
Age (11 years*) 
1.22  
(0.94, 1.58) 
0.13 
1.30  
(1.09, 1.56) 
0.003 
1.25  
(1.10, 1.42) 
0.0005 
1.41 
 (1.28, 1.56) 
<0.0001 
1.53 
(1.36, 1.71) 
<0.0001 
Race/ethnicity 
Non-Hispanic Black 
0.78  
(0.49, 1.24) 
0.08 
1.12  
(0.83, 1.52) 
0.60 
1.26  
(1.00, 1.58) 
0.12 
1.08  
(0.91, 1.29) 
0.53 
0.98  
(0.80, 1.19) 
0.61 
Other Race 
0.33  
0.12, 0.9) 
  
0.91  
(0.54, 1.52) 
  
1.04  
(0.70, 1.53) 
  
0.97  
(0.73, 1.29) 
  
0.85  
(0.61, 1.18) 
  
Female 
0.57  
(0.36, 0.91) 
0.02 
0.64  
(0.48, 0.86) 
0.003 
0.87  
(0.71, 1.08) 
0.21 
0.65  
(0.56, 0.77) 
<0.0001 
0.67  
(0.55, 0.80) 
<0.0001 
Less than High School Education 
0.71  
(0.41, 1.24) 
0.23 
0.92  
(0.66, 1.27) 
0.60 
1.17  
(0.94, 1.45) 
0.17 
0.99  
(0.83, 1.18) 
0.90 
0.98  
(0.80, 1.19) 
0.81 
Alcohol Use 
1.36  
(0.9, 2.08) 
0.15 
0.79  
(0.61, 1.03) 
0.08 
0.82  
(0.68, 0.98) 
0.03 
0.81  
(0.70, 0.94) 
0.004 
0.84  
(0.71, 0.99) 
0.04 
Current Smoker 
1.92  
(1.19, 3.11) 
0.01 
1.03  
(0.70, 1.52) 
0.86 
1.21  
(0.93, 1.58) 
0.16 
1.55  
(1.29, 1.87) 
<0.0001 
1.70  
(1.38, 2.09) 
<0.0001 
Total MET/week 
 (148*) 
1.13  
(0.94, 1.36) 
0.20 
0.87  
(0.74, 1.03) 
0.10 
0.95  
(0.86, 1.06) 
0.37 
0.88  
(0.81, 0.96) 
0.006 
0.88  
(0.79, 0.98) 
0.02 
History of CVD 
1.92  
(1.25, 2.97) 
0.003 
1.89  
(1.43, 2.49) 
<0.0001 
2.16  
(1.77, 2.64) 
<0.0001 
1.97  
(1.69, 2.30) 
<0.0001 
2.09  
(1.76, 2.49) 
<0.0001 
Diabetes 
2.12  
(1.27, 3.54) 
0.004 
1.36  
(0.99, 1.87) 
0.06 
1.61  
(1.27, 2.04) 
<0.0001 
1.25  
(1.05, 1.48) 
0.01 
1.28  
(1.05, 1.57) 
0.01 
Hypertension 
0.98  
(0.45, 2.14) 
0.96 
1.39  
(0.79, 2.46) 
0.25 
1.56  
(0.98, 2.5) 
0.06 
1.16  
(0.87, 1.54) 
0.32 
0.96  
(0.70, 1.31) 
0.80 
Systolic BP, mm Hg  
(22 mm Hg*) 
1.02  
(0.82, 1.27) 
0.83 
1.07 
 (0.94, 1.23) 
0.31 
1.13  
(1.02, 1.25) 
0.01 
1.11  
(1.03, 1.20) 
0.007 
1.09  
(1.00, 1.19) 
0.047 
BMI, kg/M
2
  
(8 kg/ M
2*
) 
0.74  
(0.58, 0.95) 
0.02 
0.86 
 (0.74, 1.00) 
0.048 
1.12  
(1.02, 1.23) 
0.02 
0.92  
(0.85, 1.00) 
0.04 
0.95  
(0.87, 1.04) 
0.28 
HDL cholesterol, mg/dL  
(16 mg/dL*) 
1.01  
(0.79, 1.29) 
0.95 
0.85  
(0.72, 1.01) 
0.07 
1.01  
(0.90, 1.13) 
0.90 
1.01  
(0.93, 1.10) 
0.85 
1.02  
(0.93, 1.13) 
0.64 
LDL cholesterol, mg/dL 
 (35 mg/dL*) 
1.1  
(0.88, 1.36) 
0.41 
1.12  
(0.98, 1.29) 
0.09 
0.92  
(0.83, 1.01) 
0.08 
1.01  
(0.94, 1.09) 
0.73 
0.98  
(0.90, 1.06) 
0.59 
Glucose, mg/dL  
(50 mg/dL*) 
1.31  
(1.14, 1.52) 
0.0002 
1.12  
(0.99, 1.26) 
0.06 
1.11  
(1.02, 1.21) 
0.02 
1.11  
(1.03, 1.18) 
0.004 
1.12  
(1.04, 1.21) 
0.003 
Log hsCRP, mg/dL  
(0.5 ml/dL*) 
1.02  
(0.81, 1.28) 
0.89 
1.18  
(1.02, 1.36) 
0.03 
1.16  
(1.04, 1.29) 
0.007 
1.21  
(1.12, 1.31) 
<0.0001 
1.19  
(1.09, 1.3) 
0.0001 
eGFR, ml/min/1.73m
2  
(14 ml/min/1.73m
2*
) 
0.71  
(0.55, 0.91) 
0.01 
0.81  
(0.69, 0.95) 
0.01 
0.76  
(0.68, 0.85) 
<0.0001 
0.79  
(0.72, 0.86) 
<0.0001 
0.77  
(0.7, 0.85) 
<0.0001 
Log urinary albumin, g/24 hours  
(0.9 g/24 hours*) 
1.47  
(1.01, 2.13) 
0.04 
1.44  
(1.11, 1.87) 
0.01 
1.79  
(1.50, 2.14) 
<0.0001 
1.42  
(1.23, 1.64) 
<0.0001 
1.38  
(1.17, 1.63) 
0.0001 
Statins 
0.77  
(0.49, 1.22) 
0.27 
1.25  
(0.93, 1.69) 
0.15 
0.99  
(0.81, 1.22) 
0.95 
0.86  
(0.74, 1.01) 
0.06 
0.79  
(0.66, 0.94) 
0.008 
ACE inhibitor or ARB 
1.13  
(0.69, 1.83) 
0.63 
0.96  
(0.71, 1.30) 
0.80 
1.07  
(0.86, 1.33) 
0.55 
0.99  
(0.84, 1.16) 
0.86 
0.97 
 (0.81, 1.17) 
0.78 
Aspirin 
1.00  
(0.66, 1.51) 
1.00 
1.39  
(1.06, 1.81) 
0.02 
0.97  
(0.80, 1.17) 
0.73 
1.01  
(0.87, 1.17) 
0.90 
0.90  
(0.77, 1.07) 
0.23 
Beta blockers 
1.29  
(0.84, 1.96) 
0.24 
1.44  
(1.09, 1.90) 
0.01 
1.51  
(1.23, 1.85) 
<0.0001 
1.23  
(1.06, 1.43) 
0.007 
1.20  
(1.01, 1.42) 
0.04 
Clinic Center 
Cleveland Clinic Foundation 
1.23  
(0.47, 3.22) 
0.47 
0.95  
(0.43, 2.09) 
0.02 
0.91  
(0.54, 1.53) 
0.01 
0.76  
(0.50, 1.17) 
0.04 
0.63  
(0.38, 1.04) 
0.006 
Kaiser Permanente of Northern 
California 
1.44  
(0.6, 3.43) 
  
2.27  
(1.32, 3.88) 
  
1.13  
(0.75, 1.71) 
  
1.14  
(0.84, 1.54) 
  
0.83  
(0.57, 1.20) 
  
Metro health Medical Center 
1.19  
(0.37, 3.83) 
  
2.28  
(1.19, 4.38) 
  
1.08  
(0.64, 1.83) 
  
1.16  
(0.78, 1.74) 
  
0.92  
(0.56, 1.50) 
  
St. Johns Health System 
1.01  
(0.28, 3.66) 
  
2.09  
(1.02, 4.27) 
  
0.85  
(0.47, 1.52) 
  
1.10  
(0.72, 1.69) 
  
0.77  
(0.45, 1.31) 
  
The Johns Hopkins University 
1.08  
(0.41, 2.83) 
  
1.27  
(0.66, 2.44) 
  
1.49  
(0.98, 2.26) 
  
1.08  
(0.78, 1.5) 
  
1.11  
(0.76, 1.60) 
  
Tulane University Health Science 
Center 
2.08  
(0.99, 4.35) 
  
1.89  
(1.11, 3.22) 
  
1.72  
(1.20, 2.47) 
  
1.37  
(1.03, 1.82) 
  
1.45  
(1.06, 1.98) 
  
University Hospital of Cleveland 
1.08  
(0.37, 3.12) 
  
2.25  
(1.21, 4.17) 
  
1.49  
(0.95, 2.34) 
  
1.48  
(1.05, 2.08) 
  
1.00  
(0.65, 1.52) 
  
University of California, San 
Francisco 
0.55  
(0.07, 4.39) 
  
1.46  
(0.54, 3.95) 
  
0.68  
(0.27, 1.72) 
  
0.87  
(0.48, 1.57) 
  
0.75  
(0.37, 1.52) 
  
University of Illinois at Chicago 
1.21  
(0.54, 2.7) 
  
1.10 
(0.63, 1.95) 
  
1.05  
(0.72, 1.53) 
  
1.04  
(0.78, 1.38) 
  
1.19  
(0.87, 1.64) 
  
University of Maryland 
0.74  
(0.25, 2.18) 
  
1.50  
(0.82, 2.73) 
  
1.17  
(0.77, 1.79) 
  
1.44  
(1.06, 1.95) 
  
1.48  
(1.05, 2.07) 
  
University of Michigan 
1.34  
(0.55, 3.31) 
  
1.24  
(0.63, 2.45) 
  
0.72  
(0.42, 1.22) 
  
0.97  
(0.68, 1.38) 
  
0.83  
(0.55, 1.24) 
  
*one standard deviation 
ABI= ankle brachial index; MET= metabolic equivalent of task; CVD= cardiovascular disease; BP= blood pressure; HDL= high-density lipoprotein; LDL= ow-density lipoprotein; hsCRP=high-
sensitivity C-reactive protein; eGFR=estimated glomerular filtration rate; ACE= angiotensin Converting Enzyme; ARB= angiotensin II receptor blockers 
